1cBio and Lee's Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio's PARP1 Inhibitor OC-3 for Oncology in Greater China and Southeast Asia

PartnershipOC-3Positive

AI Analysis

Summary

1cBio and Lee's Pharmaceutical Holdings Limited entered an exclusive licensing agreement for OC-3, a PARP1 inhibitor for oncology, in Greater China and Southeast Asia. 1cBio will receive up to US$27 million in upfront, development, and potential sales milestone payments.

Outcome Details

Exclusive licensing agreement for development and commercialization rights

Importance:7/10

Sentiment:

0.70

licensingpartnershipPARP1 inhibitoroncologyGreater ChinaSoutheast Asia

Related Companies

$INTI $DFPH $GCAN $CHHE

Read the original article

Published by PR Newswire Biotech on September 9, 2026 12:00 PM

Read Original